
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
The global oncology market is expected to see strong growth over the next decade, with ResearchAndMarkets forecasting it to reach US$866.1 billion by 2034 at a 10.8% CAGR. A separate estimate from Vision Research Reports projects the market will surpass US$903.81 billion by the same year, growing at a 10.9% CAGR.
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new phase of leadership with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. Kelly brings a background in high-stakes biotech transactions and strategic immuno-oncology development, positioning him to guide the company through its next stage of clinical and business evolution.
Before joining Oncolytics, Kelly served as General Counsel at Ambrx Biopharma, where he played a key role in its $2 billion acquisition by Johnson & Johnson. His earlier work includes advising life sciences firms on licensing, partnerships, and M&A while at Kirkland & Ellis LLP and Lowenstein Sandler LLP. Now leading Oncolytics, he steps into a company advancing pelareorep, a virus-based immunotherapeutic designed to work synergistically with checkpoint inhibitors and other agents across a range of solid and blood cancers.
"Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders."
Kelly's appointment signals a clear strategic focus: advancing pelareorep toward key late-stage milestones through a capital-conscious approach that remains open to strategic collaboration.
Pelareorep currently holds FDA Fast Track designation for both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —a rare dual recognition that underscores its regulatory momentum. Across multiple studies, the virus-based therapy has demonstrated consistent immune activation, broad combinability with checkpoint inhibitors and chemotherapies, and encouraging response rates in challenging cancer types.
In mPDAC, pelareorep has achieved over 60% objective response rates in tumor-evaluable patients across Phase 1 and 2 trials—more than double what's typically seen in historical benchmarks. Separate analyses also reported two-year survival rates four to six times higher than control arms or prior studies. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed survival benefits supportive of further investigation.
Meanwhile, a Phase 2 cohort in anal cancer pairing pelareorep with a checkpoint inhibitor reported partial or complete responses in nearly half of evaluable patients—substantially higher than historical norms for monotherapy in this setting.
"Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors."
Kelly's compensation package includes equity grants and milestone-linked incentives tied to future financings and potential strategic transactions—aligning leadership priorities with long-term shareholder interests. The structure signals a commitment to advancing both clinical and corporate goals while preserving balance sheet discipline and maintaining appeal for potential partners.
With multiple cohorts progressing in the GOBLET study—including those in pancreatic and anal cancer supported by external funding and regulatory engagement— Oncolytics is positioned to move forward with a combination of scientific momentum, financial agility, and renewed strategic focus.
In other recent industry developments and happenings in the market include:
Immuneering Corporation (NASDAQ: IMRX) reported positive Phase 2a data for atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. At six months, the study showed 94% overall survival and 72% progression-free survival in 34 patients, with no median OS or PFS reached yet.
"These exceptional data demonstrate the potential of atebimetinib plus mGnP to dramatically extend the lives of patients with advanced pancreatic cancer," said Ben Zeskind, Ph.D., Co-founder and CEO of Immuneering. "Our ultimate goal is to help cancer patients outlive their disease, and today's announcement represents an important milestone on that journey."
The combination also demonstrated a 39% overall response rate, an 81% disease control rate, and a notably favorable tolerability profile. Many patients experienced deep, durable tumor regressions, including lesions rendered undetectable. The regimen was well tolerated, with an adverse event profile suggesting potential best-in-class positioning among MEK inhibitors.
GRAIL, Inc. (NASDAQ: GRAL), recently announced strong top-line results from the PATHFINDER 2 registrational study evaluating its Galleri® multi-cancer early detection test in over 25,000 adults.
"We are delighted to see very encouraging performance of the Galleri MCED test as a cancer screening tool in broad intended use populations of asymptomatic adults over 50 years of age in both the PATHFINDER 2 study and the NHS-Galleri trial's prevalent screening round," said Josh Ofman, MD, MSHS, President at GRAIL. "We would like to extend our sincere gratitude to all of the participants and investigators in both of these pivotal studies, who are collectively helping to realize the potential of this groundbreaking technology for population-scale multi-cancer early detection and move the field forward."
The study showed a substantially higher positive predictive value (PPV) compared to the original PATHFINDER trial, with consistent specificity and cancer signal origin accuracy, and no serious safety concerns reported. GRAIL plans to submit these results to the FDA as part of its ongoing premarket approval process under Breakthrough Device Designation.
Intensity Therapeutics, Inc. (NASDAQ: INTS) announced that the first patients in its ongoing Phase 2 INVINCIBLE-4 trial achieved high levels of tumor necrosis within eight days of receiving two doses of INT230-6, before starting standard-of-care immunochemotherapy for triple-negative breast cancer (TNBC).
"We are excited to see that INT230-6 is achieving meaningful levels of necrosis in patients with evidence of immune activation," said Lewis H. Bender, President and CEO of Intensity. "TNBC patients risk their lives to achieve a pCR, and about forty percent fail to achieve the desired result."
MRI scans showed substantial tumor destruction and inflammation, suggesting immune activation following direct intratumoral injection. The randomized study compares INT230-6 followed by standard treatment versus standard treatment alone, with pathological complete response (pCR) as the primary endpoint.
Relay Therapeutics, Inc. (NASDAQ: RLAY) reported updated interim data from its Phase 1/2 study of RLY-2608 plus fulvestrant, showing a median progression-free survival (PFS) of 11.0 months in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.
"We are encouraged by the consistency of these updated RLY-2608 + fulvestrant data, which continue to show the potential benefit of a mutant-selective PI3Kα inhibitor for improving both the tolerability profile and progression free survival compared to standard of care," said Don Bergstrom, M.D., Ph.D., President of R&D at Relay Therapeutics. "We look forward to starting the first mutant-selective PI3Kα Phase 3 trial, ReDiscover-2, in the middle of this year."
Among patients at the recommended Phase 3 dose, the clinical benefit rate reached 67%, and 39% had confirmed partial responses, with notably higher response rates in those with kinase mutations. The combination maintained a favorable tolerability profile, with low rates of high-grade adverse events and minimal treatment discontinuations.
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
3 hours ago
- Cision Canada
KEENON Debuts First Bipedal Humanoid Service Robot at WAIC, Showcasing Role-Specific Embodied AI Solutions
SHANGHAI, July 26, 2025 /CNW/ -- The world premiere of KEENON Robotics' bipedal humanoid service robot, XMAN-F1, takes center stage at the World Artificial Intelligence Conference (WAIC) 2025 in Shanghai from July 26 to 29, where the pioneer in embodied intelligence showcases its latest innovations on the global stage for breakthrough AI advancements. Transforming its showground into an Embodied Service Experience Hub, KEENON immerses visitors in three interactive scenarios—medical station, lounge bar, and performance space—highlighting how embodied AI solution is actively reshaping future lifestyles and industrial ecosystems. At the event, XMAN-F1 emerges as the core interactive demonstration, showcasing human-like mobility and precision in service tasks across diverse scenarios. From preparing popcorn to mixing personalized chilled beverages such as Sprite or Coke with adjustable ice levels, the robot demonstrates remarkable environmental adaptability and task execution. Scheduled stage appearances feature XMAN-F1 autonomously delivering digital presentations and product demos, powered by multimodal interaction and large language model technologies. Its fluid movements and naturalistic gestures establish it as the primary focus of attention, with visitors gathering to witness its engagement live. The demonstration spotlights further multi-robot collaboration in specialized environments. At the medical station, the humanoid XMAN-F1 partners with logistics robot M104 to create a closed-loop smart healthcare solution. The bar area features a highlight collaboration with Johnnie Walker Blue Label—the world's leading premium whisky—where robotic bartenders work alongside delivery robot T10 to craft and serve bespoke beverages. The seamless multi-robot integration not only enhances operational efficiency but signals the dawn of robotic system interoperability, moving far beyond single-task automation. According to IDC's latest report, KEENON leads the commercial service robot sector with 22.7% of global shipments and holds a definitive 40.4% share in food delivery robotics. At WAIC 2025, the company reinforces its market leadership while presenting its ecosystem-based strategy for cross-scenario embodied intelligence solutions. Looking ahead, KEENON will continue driving innovation in embodied intelligence, combining cutting-edge R&D and global partnerships to unlock the full potential of 'Robotics+' applications worldwide.


CBC
5 hours ago
- CBC
Three rescued mine workers on their way home
July 25, 2025 | The three rescued drillers are on their way home after 60 hours deep underground in a B.C. mine. Also, it's looking increasingly unlikely Canada and the U.S. will ink a trade deal by Aug. 1. And the Trump administration's meetings with Ghislaine Maxwell.


Winnipeg Free Press
5 hours ago
- Winnipeg Free Press
Despite cancellation, Colbert's deft late-night punches will continue to land
Opinion Getting hit in the funny bone is painful, so last week's news about the firing of Stephen Colbert really hurt. He's a funny guy, and funniness is not just good right now. It's necessary. But there are other reasons this comedy cancellation feels bad. On July 17, Colbert announced that his contract would not be renewed and that CBS would shut down the entire Late Show in May. This came three days after the 61-year-old host used his monologue to call out CBS's decision to pay US$16 million to settle Donald Trump's lawsuit — seen by most legal experts as meritless — against 60 Minutes. Stephen Colbert (Scott Kowalchyk / CBS) In his comic bit, Colbert implied the payment was meant to smooth the way for the Trump administration's approval of the US$8-billion merger of CBS parent company Paramount Global with Skydance Media. According to Colbert, 'the technical name in legal circles' for this action is a 'big, fat bribe.' The timing of the cancellation announcement and CBS's insistence that it was 'purely a financial decision' have led to a lot of talk. There's talk about the economics of a changing entertainment landscape and the conflicts of interest that can arise as media ownership is absorbed into increasingly massive corporate conglomerates. There's talk about Trump using the power of the American presidency as a form of financial extortion to crack down on the free expression of law firms, universities and media outlets he despises. Finally, there's talk about the real value — beyond dollars and cents — of comedy, especially in our fraught era. While the reasons behind CBS's decision might not be purely financial, there are economic issues at play. The Late Show with Stephen Colbert employs about 200 people, costs about US$100 million to produce annually and reportedly lost about US$40 million last year. There are other numbers, though: Colbert currently leads the late-night ratings, giving his network some much-needed pop-culture currency. The Late Show certainly generates more buzz than, say, Tracker, the CBS primetime show that Colbert has been gently mocking for two seasons. (I only know of the existence of Tracker, about a 'lone-wolf survivalist' who uses his skills to find missing persons, because of Colbert's jokes about it. And I suspect I'm not alone.) Still, while Colbert might win the late-night ratings race, it's also true late night's overall audience is a dwindling demographic. After the mid-20th-century heyday of Jack Paar and Johnny Carson, the snarkier David Letterman captured and held a younger audience for a while, but viewership for network television has been steadily declining in recent years, as have ad revenues. (And I don't really have any right to complain here. I have never watched the whole show on the television box at 11:35 p.m. Like most people, I catch up on late-night monologues on YouTube the next day.) These bottom-line financial issues are just one part of a bigger problem, however, now that CBS has gotten into a Trumpy quagmire that involves both the serious news show 60 Minutes and The Late Show, which often covers some of the same ground except with prop comedy. When networks are owned by huge parent companies, it becomes much more likely that the journalistic imperative to serve the public interest will clash with the business interests of shareholders. The proposed merger between Paramount and Skydance involves two Succession-style billionaire dynasties with all kinds of holdings, so it's no surprise things are getting sticky. Running an effective news program — or even a comedy show that comments on politics and current events — needs to be rooted in the belief democracy requires informed citizens. Colbert's commitment to the American experiment is deeply, deeply earnest, which is why he can be so funny about it. Not everyone is laughing, of course. While the Trump admin likes to complain about 'cancel culture,' it seems to love actual cancellations. After Colbert's announcement, Trump proclaimed on social media, 'I absolutely love that Colbert got fired,' while hinting that Jimmy Kimmel is 'NEXT to go.' The White House also issued a statement about The View after co-host Joy Behar suggested Trump was jealous of Obama. With all the corporate capitulation going on, Trump's attacks on TV hosts could have a chilling effect on free speech. Colbert, having been fired already, seems to be well positioned to talk back. Wednesdays A weekly dispatch from the head of the Free Press newsroom. He has a staff of good comedy writers. His delivery is nimble, his timing is deft. But more than that, he has a particular comic vibe that's very effective against Trump. His style is precise, even prim, at times. He's got that adorably dorky Lord of the Rings obsession. He has nice manners. While the shamelessness of Donald Trump means his scandals practically come pre-satirized, there's something about Colbert's approach — sharp but not cheap — that punctures that self-sealing bubble. When Colbert says of Trump, 'I don't care for him,' it lands. And this last week, as Colbert started off his monologue with his usual intro — saying, 'I'm your host Stephen Colbert,'— the roar of response from the live audience was palpable, suggesting good things for his inevitable future podcast. Trump has been dealing with a lot of unintended consequences in recent days. He might end up being less than happy about the Colbert firing. Lame-duck politicians struggle to get anything done. Outgoing comedians, on the other hand, can do a whole lot. Alison GillmorWriter Studying at the University of Winnipeg and later Toronto's York University, Alison Gillmor planned to become an art historian. She ended up catching the journalism bug when she started as visual arts reviewer at the Winnipeg Free Press in 1992. Read full biography Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber. Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.